0.57
+0.88%
Close of 6 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BlinkLab
Its shares trade on ASX under the ticker BB1.AX. It has been listed since 4 April 2024. In the fiscal year to 30 June 2025, it reported revenue of A$375,550 and a net loss of A$5.7m. At that date it held total assets of A$9.7m and shareholders' equity of A$9.0m.
An app that turns an ordinary mobile phone into a device for conducting objective neurobehavioral tests could make it easier and more cost-effective to diagnose neurological disorders. The company is headquartered in Sydney, New South Wales. The company went IPO on 2024-04-04. The Company’s tests include eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI) and habituation of eye blink response, which serve as biomarkers for neurological and psychiatric disorders (BlinkLab Tests). The BlinkLab Device (BlinkLab Dx) consists of BlinkLab App, a mobile application for patients, caregivers and/or parents, effectively a front-end tool that helps collect test subjects’ information and responses to the BlinkLab Tests in real time (BlinkLab App), and BlinkLab Portal, which includes a fully built secure database and content management system (CMS) as well as experimenter’s portal that allows for full customization of the neurometric tests as well as data analysis, annotation and visualization tools (the BlinkLab Portal).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 4 Apr 2024
- Website
- blinklab.org ↗
Leadership
Pay as last reported
- Mr. Brian LeedmanIndependent Non-Executive Chairman of the Board
- Dr. Hendrikus BoeleProposed Chief Executive Officer
- Mr. Cornelis BoeleProposed Chief Technology Officer
- Dr. Sebastiaan KoekkoekProposed Chief Scientific Officer
- Dr. Anton UvarovExecutive Director
- Mr. Christopher AchurchProposed Company Secretary
- Ms. Kamille DietrichCompany Secretary
- Dr. Richard HopkinsNon-Executive Independent Director
- Ms. Jane MorganNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BlinkLab Dx app enables real-time neurobehavioral testing on mobile devices
- BlinkLab Portal offers secure database and customizable neurometric test tools
- BlinkLab Tests include eyeblink conditioning and prepulse inhibition biomarkers
Weaknesses
- BlinkLab App requires mobile phone for patient testing
- BlinkLab Portal needs secure database for data management
- BlinkLab Tests focus on specific neurological biomarkers only
Opportunities
- BlinkLab could expand to psychiatric disorder diagnostics
- BlinkLab may partner with Australian health providers
- BlinkLab might target global health care markets
Threats
- BlinkLab faces competition from established health tech firms
- BlinkLab must comply with Australian health regulations
- BlinkLab risks data security breaches in mobile testing
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.